Lormetazepam

Oral
Short-term management of insomnia

May be taken with or without food.

CNS depression; respiratory depression, acute pulmonary insufficiency or sleep apnoea; severe hepatic impairment; chronic psychosis, phobic or obsessional states; not to be used alone to treat depression or associated anxiety; unstable myasthenia gravis; glaucoma. Pregnancy and lactation, children

Chronic pulmonary insufficiency; elderly or debilitated patients; muscle weakness, impaired liver or kidney function; personality disorders or organic brain changes; history of alcohol or drug addiction.

Drowsiness and lightheadedness, muscle weakness and ataxia, vertigo, headache, confusion, depression, slurred speech, changes in libido, tremor, visual disturbances, urinary retention, GI disturbances, changes in salivation and amnesia.

Enhanced sedation or respiratory and CV depression with drugs with CNS depressant properties eg, antidepressants, antihistamines, antipsychotics, general anaesthetics, other hypnotics or sedatives, opioid analgesics and alcohol.

Description: Lormetazepam is a short-acting benzodiazepine hypnotic.
Pharmacokinetics:
Absorption: Readily absorbed from the GI tract.
Metabolism: Metabolised to inactive glucuronide.
Excretion: Terminal half life of around 11 hr.

Hypnotics & Sedatives